Wellington Management Group LLP Gemini Therapeutics, Inc. Transaction History

Wellington Management Group LLP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $2.31 Million - $4.42 Million	-700,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.32 - $14.02 $4.93 Million - $10.9 Million	-779,954 Reduced 52.7%	700,000 $4.53 Million
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $16.8 Million - $26.6 Million	1,479,954 New	1,479,954 $19.7 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.